Open Access

TRIB2 regulates the expression of miR‑33a‑5p through the ERK/c‑Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells

  • Authors:
    • Hang Sun
    • Youjie Li
    • Xiao Wang
    • Xue Zhou
    • Simin Rong
    • Dongmin Liang
    • Guangbin Sun
    • Huizhen Cao
    • Hongfang Sun
    • Ranran Wang
    • Yunfei Yan
    • Shuyang Xie
    • Yunxiao Sun
  • View Affiliations

  • Published online on: March 17, 2022     https://doi.org/10.3892/ijo.2022.5339
  • Article Number: 49
  • Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chronic myeloid leukemia (CML) is a hematological disease, and imatinib (IM) resistance represents a major problem for its clinical treatment. In the present study, the role of tribbles pseudokinase 2 (TRIB2) in IM resistance of CML and the possible mechanism were investigated. It was found that TRIB2 was highly expressed in IM‑resistant patients with CML through the Oncomine database and this conclusion was confirmed using reverse transcription‑quantitative PCR and western blot experiments. Knockdown of TRIB2 was found to increase the drug sensitivity of KG cells to IM using Cell‑Counting Kit‑8 (CCK‑8) assays, and the low‑expression TRIB2 mice were further found to be more sensitive to the IM and have a higher survival rate in leukemia model mice. Moreover, using western blot and luciferase experiments, it was found that TRIB2 could regulate c‑Fos through the ERK signaling pathway, and c‑Fos suppressed the transcriptional activity and the expression of miR‑33a‑5p. Further investigation identified that the binding site for c‑Fos to function on miR‑33a‑5p was the ‑958‑965 region. Finally, CCK‑8 assays and western blot experiments demonstrated that miR‑33a‑5p could inhibit the proliferation of KG cells and reduce IM resistance by suppressing the expression of HMGA2. In conclusion, it was demonstrated that TRIB2 regulates miR‑33a‑5p to reverse IM resistance in CML, which may help identify novel targets and therapeutic strategies for the clinical treatment of IM resistance.
View Figures
View References

Related Articles

Journal Cover

May-2022
Volume 60 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sun H, Li Y, Wang X, Zhou X, Rong S, Liang D, Sun G, Cao H, Sun H, Wang R, Wang R, et al: TRIB2 regulates the expression of miR‑33a‑5p through the ERK/c‑Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells. Int J Oncol 60: 49, 2022
APA
Sun, H., Li, Y., Wang, X., Zhou, X., Rong, S., Liang, D. ... Sun, Y. (2022). TRIB2 regulates the expression of miR‑33a‑5p through the ERK/c‑Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells. International Journal of Oncology, 60, 49. https://doi.org/10.3892/ijo.2022.5339
MLA
Sun, H., Li, Y., Wang, X., Zhou, X., Rong, S., Liang, D., Sun, G., Cao, H., Sun, H., Wang, R., Yan, Y., Xie, S., Sun, Y."TRIB2 regulates the expression of miR‑33a‑5p through the ERK/c‑Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells". International Journal of Oncology 60.5 (2022): 49.
Chicago
Sun, H., Li, Y., Wang, X., Zhou, X., Rong, S., Liang, D., Sun, G., Cao, H., Sun, H., Wang, R., Yan, Y., Xie, S., Sun, Y."TRIB2 regulates the expression of miR‑33a‑5p through the ERK/c‑Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells". International Journal of Oncology 60, no. 5 (2022): 49. https://doi.org/10.3892/ijo.2022.5339